IBDEI2RH ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,44043,1,4,0)
;;=4^G25.79
;;^UTILITY(U,$J,358.3,44043,2)
;;=^5003800
;;^UTILITY(U,$J,358.3,44044,0)
;;=T43.205A^^164^2176^4
;;^UTILITY(U,$J,358.3,44044,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44044,1,3,0)
;;=3^Antidepressant Discontinuation Syndrome,Init Encntr
;;^UTILITY(U,$J,358.3,44044,1,4,0)
;;=4^T43.205A
;;^UTILITY(U,$J,358.3,44044,2)
;;=^5050540
;;^UTILITY(U,$J,358.3,44045,0)
;;=T43.205D^^164^2176^5
;;^UTILITY(U,$J,358.3,44045,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44045,1,3,0)
;;=3^Antidepressant Discontinuation Syndrome,Subseq Encntr
;;^UTILITY(U,$J,358.3,44045,1,4,0)
;;=4^T43.205D
;;^UTILITY(U,$J,358.3,44045,2)
;;=^5050541
;;^UTILITY(U,$J,358.3,44046,0)
;;=T43.205S^^164^2176^6
;;^UTILITY(U,$J,358.3,44046,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44046,1,3,0)
;;=3^Antidepressant Discontinuation Syndrome,Sequela
;;^UTILITY(U,$J,358.3,44046,1,4,0)
;;=4^T43.205S
;;^UTILITY(U,$J,358.3,44046,2)
;;=^5050542
;;^UTILITY(U,$J,358.3,44047,0)
;;=G25.71^^164^2176^7
;;^UTILITY(U,$J,358.3,44047,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44047,1,3,0)
;;=3^Medication-Induced Acute Akathisia
;;^UTILITY(U,$J,358.3,44047,1,4,0)
;;=4^G25.71
;;^UTILITY(U,$J,358.3,44047,2)
;;=^5003799
;;^UTILITY(U,$J,358.3,44048,0)
;;=G24.02^^164^2176^8
;;^UTILITY(U,$J,358.3,44048,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44048,1,3,0)
;;=3^Medication-Induced Acute Dystonia
;;^UTILITY(U,$J,358.3,44048,1,4,0)
;;=4^G24.02
;;^UTILITY(U,$J,358.3,44048,2)
;;=^5003785
;;^UTILITY(U,$J,358.3,44049,0)
;;=G21.0^^164^2176^12
;;^UTILITY(U,$J,358.3,44049,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44049,1,3,0)
;;=3^Neuroleptic Malignant Syndrome
;;^UTILITY(U,$J,358.3,44049,1,4,0)
;;=4^G21.0
;;^UTILITY(U,$J,358.3,44049,2)
;;=^5003771
;;^UTILITY(U,$J,358.3,44050,0)
;;=T50.905A^^164^2176^1
;;^UTILITY(U,$J,358.3,44050,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44050,1,3,0)
;;=3^Adverse Effect of Medication,Other,Init Encntr
;;^UTILITY(U,$J,358.3,44050,1,4,0)
;;=4^T50.905A
;;^UTILITY(U,$J,358.3,44050,2)
;;=^5052160
;;^UTILITY(U,$J,358.3,44051,0)
;;=T50.905S^^164^2176^2
;;^UTILITY(U,$J,358.3,44051,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44051,1,3,0)
;;=3^Adverse Effect of Medication,Other,Sequela
;;^UTILITY(U,$J,358.3,44051,1,4,0)
;;=4^T50.905S
;;^UTILITY(U,$J,358.3,44051,2)
;;=^5052162
;;^UTILITY(U,$J,358.3,44052,0)
;;=T50.905D^^164^2176^3
;;^UTILITY(U,$J,358.3,44052,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44052,1,3,0)
;;=3^Adverse Effect of Medication,Other,Subseq Encntr
;;^UTILITY(U,$J,358.3,44052,1,4,0)
;;=4^T50.905D
;;^UTILITY(U,$J,358.3,44052,2)
;;=^5052161
;;^UTILITY(U,$J,358.3,44053,0)
;;=F45.22^^164^2177^1
;;^UTILITY(U,$J,358.3,44053,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44053,1,3,0)
;;=3^Body Dysmorphic D/O
;;^UTILITY(U,$J,358.3,44053,1,4,0)
;;=4^F45.22
;;^UTILITY(U,$J,358.3,44053,2)
;;=^5003588
;;^UTILITY(U,$J,358.3,44054,0)
;;=F63.3^^164^2177^8
;;^UTILITY(U,$J,358.3,44054,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44054,1,3,0)
;;=3^Trichotillomania (Hair-Pulling D/O)
;;^UTILITY(U,$J,358.3,44054,1,4,0)
;;=4^F63.3
;;^UTILITY(U,$J,358.3,44054,2)
;;=^5003643
;;^UTILITY(U,$J,358.3,44055,0)
;;=F06.8^^164^2177^4
;;^UTILITY(U,$J,358.3,44055,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,44055,1,3,0)
;;=3^OCD & Rel D/O d/t Phys Cond
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI2RH 3789 printed Apr 09, 2024@21:13:03 Page 2
IBDEI2RH ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,44043,1,4,0)
+2 ;;=4^G25.79
+3 ;;^UTILITY(U,$J,358.3,44043,2)
+4 ;;=^5003800
+5 ;;^UTILITY(U,$J,358.3,44044,0)
+6 ;;=T43.205A^^164^2176^4
+7 ;;^UTILITY(U,$J,358.3,44044,1,0)
+8 ;;=^358.31IA^4^2
+9 ;;^UTILITY(U,$J,358.3,44044,1,3,0)
+10 ;;=3^Antidepressant Discontinuation Syndrome,Init Encntr
+11 ;;^UTILITY(U,$J,358.3,44044,1,4,0)
+12 ;;=4^T43.205A
+13 ;;^UTILITY(U,$J,358.3,44044,2)
+14 ;;=^5050540
+15 ;;^UTILITY(U,$J,358.3,44045,0)
+16 ;;=T43.205D^^164^2176^5
+17 ;;^UTILITY(U,$J,358.3,44045,1,0)
+18 ;;=^358.31IA^4^2
+19 ;;^UTILITY(U,$J,358.3,44045,1,3,0)
+20 ;;=3^Antidepressant Discontinuation Syndrome,Subseq Encntr
+21 ;;^UTILITY(U,$J,358.3,44045,1,4,0)
+22 ;;=4^T43.205D
+23 ;;^UTILITY(U,$J,358.3,44045,2)
+24 ;;=^5050541
+25 ;;^UTILITY(U,$J,358.3,44046,0)
+26 ;;=T43.205S^^164^2176^6
+27 ;;^UTILITY(U,$J,358.3,44046,1,0)
+28 ;;=^358.31IA^4^2
+29 ;;^UTILITY(U,$J,358.3,44046,1,3,0)
+30 ;;=3^Antidepressant Discontinuation Syndrome,Sequela
+31 ;;^UTILITY(U,$J,358.3,44046,1,4,0)
+32 ;;=4^T43.205S
+33 ;;^UTILITY(U,$J,358.3,44046,2)
+34 ;;=^5050542
+35 ;;^UTILITY(U,$J,358.3,44047,0)
+36 ;;=G25.71^^164^2176^7
+37 ;;^UTILITY(U,$J,358.3,44047,1,0)
+38 ;;=^358.31IA^4^2
+39 ;;^UTILITY(U,$J,358.3,44047,1,3,0)
+40 ;;=3^Medication-Induced Acute Akathisia
+41 ;;^UTILITY(U,$J,358.3,44047,1,4,0)
+42 ;;=4^G25.71
+43 ;;^UTILITY(U,$J,358.3,44047,2)
+44 ;;=^5003799
+45 ;;^UTILITY(U,$J,358.3,44048,0)
+46 ;;=G24.02^^164^2176^8
+47 ;;^UTILITY(U,$J,358.3,44048,1,0)
+48 ;;=^358.31IA^4^2
+49 ;;^UTILITY(U,$J,358.3,44048,1,3,0)
+50 ;;=3^Medication-Induced Acute Dystonia
+51 ;;^UTILITY(U,$J,358.3,44048,1,4,0)
+52 ;;=4^G24.02
+53 ;;^UTILITY(U,$J,358.3,44048,2)
+54 ;;=^5003785
+55 ;;^UTILITY(U,$J,358.3,44049,0)
+56 ;;=G21.0^^164^2176^12
+57 ;;^UTILITY(U,$J,358.3,44049,1,0)
+58 ;;=^358.31IA^4^2
+59 ;;^UTILITY(U,$J,358.3,44049,1,3,0)
+60 ;;=3^Neuroleptic Malignant Syndrome
+61 ;;^UTILITY(U,$J,358.3,44049,1,4,0)
+62 ;;=4^G21.0
+63 ;;^UTILITY(U,$J,358.3,44049,2)
+64 ;;=^5003771
+65 ;;^UTILITY(U,$J,358.3,44050,0)
+66 ;;=T50.905A^^164^2176^1
+67 ;;^UTILITY(U,$J,358.3,44050,1,0)
+68 ;;=^358.31IA^4^2
+69 ;;^UTILITY(U,$J,358.3,44050,1,3,0)
+70 ;;=3^Adverse Effect of Medication,Other,Init Encntr
+71 ;;^UTILITY(U,$J,358.3,44050,1,4,0)
+72 ;;=4^T50.905A
+73 ;;^UTILITY(U,$J,358.3,44050,2)
+74 ;;=^5052160
+75 ;;^UTILITY(U,$J,358.3,44051,0)
+76 ;;=T50.905S^^164^2176^2
+77 ;;^UTILITY(U,$J,358.3,44051,1,0)
+78 ;;=^358.31IA^4^2
+79 ;;^UTILITY(U,$J,358.3,44051,1,3,0)
+80 ;;=3^Adverse Effect of Medication,Other,Sequela
+81 ;;^UTILITY(U,$J,358.3,44051,1,4,0)
+82 ;;=4^T50.905S
+83 ;;^UTILITY(U,$J,358.3,44051,2)
+84 ;;=^5052162
+85 ;;^UTILITY(U,$J,358.3,44052,0)
+86 ;;=T50.905D^^164^2176^3
+87 ;;^UTILITY(U,$J,358.3,44052,1,0)
+88 ;;=^358.31IA^4^2
+89 ;;^UTILITY(U,$J,358.3,44052,1,3,0)
+90 ;;=3^Adverse Effect of Medication,Other,Subseq Encntr
+91 ;;^UTILITY(U,$J,358.3,44052,1,4,0)
+92 ;;=4^T50.905D
+93 ;;^UTILITY(U,$J,358.3,44052,2)
+94 ;;=^5052161
+95 ;;^UTILITY(U,$J,358.3,44053,0)
+96 ;;=F45.22^^164^2177^1
+97 ;;^UTILITY(U,$J,358.3,44053,1,0)
+98 ;;=^358.31IA^4^2
+99 ;;^UTILITY(U,$J,358.3,44053,1,3,0)
+100 ;;=3^Body Dysmorphic D/O
+101 ;;^UTILITY(U,$J,358.3,44053,1,4,0)
+102 ;;=4^F45.22
+103 ;;^UTILITY(U,$J,358.3,44053,2)
+104 ;;=^5003588
+105 ;;^UTILITY(U,$J,358.3,44054,0)
+106 ;;=F63.3^^164^2177^8
+107 ;;^UTILITY(U,$J,358.3,44054,1,0)
+108 ;;=^358.31IA^4^2
+109 ;;^UTILITY(U,$J,358.3,44054,1,3,0)
+110 ;;=3^Trichotillomania (Hair-Pulling D/O)
+111 ;;^UTILITY(U,$J,358.3,44054,1,4,0)
+112 ;;=4^F63.3
+113 ;;^UTILITY(U,$J,358.3,44054,2)
+114 ;;=^5003643
+115 ;;^UTILITY(U,$J,358.3,44055,0)
+116 ;;=F06.8^^164^2177^4
+117 ;;^UTILITY(U,$J,358.3,44055,1,0)
+118 ;;=^358.31IA^4^2
+119 ;;^UTILITY(U,$J,358.3,44055,1,3,0)
+120 ;;=3^OCD & Rel D/O d/t Phys Cond
